Patents by Inventor Ryan T. Gill

Ryan T. Gill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240093241
    Abstract: Described herein are method for generating a vector for editing a cell. The method comprises ligating into a vector that encodes a portion of a gRNA a cassette comprising at least one editing cassette, a promoter, and a gene encoding another portion of the gRNA. Upon ligation, the portion of the gRNA from the editing cassette and the other portion of the gRNA are ligated and form a functional gRNA.
    Type: Application
    Filed: May 26, 2023
    Publication date: March 21, 2024
    Inventors: Andrew Garst, Ryan T Gill
  • Publication number: 20230407342
    Abstract: The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
    Type: Application
    Filed: March 24, 2023
    Publication date: December 21, 2023
    Inventors: Ryan T. GILL, Tanya WARNECKE, Andrea BARGHETTI, Line Dahl POULSEN
  • Publication number: 20230357796
    Abstract: Embodiments disclosed herein include novel nucleic acid-guided nucleases, novel guide nucleic acids, and novel targetable nuclease systems, and methods of use. In some embodiments, engineered non-naturally occurring nucleic acid-guided nucleases, can be used with known guide nucleic acids in a targetable nuclease system. In certain embodiments, targetable nuclease systems can be used to edit targeted genomes of humans and other species. In some embodiments, methods include, but are not limited to, recursive genetic engineering and trackable genetic engineering methods.
    Type: Application
    Filed: November 23, 2020
    Publication date: November 9, 2023
    Applicant: DANMARKS TEKNISKE UNIVERSITET
    Inventors: Ryan T. GILL, Tanya WARNECKE, Dominika Joanna JEDRZEJCZYK
  • Publication number: 20230340438
    Abstract: Embodiments disclosed herein include novel nucleic acid-guided nucleases, novel guide nucleic acids, and novel targetable nuclease systems, and methods of use. In some embodiments, engineered non-naturally occurring nucleic acid-guided nucleases, can be used with known guide nucleic acids in a targetable nuclease system. In certain embodiments, targetable nuclease systems can be used to edit targeted genomes of humans and other species. In some embodiments, methods include, but are not limited to, recursive genetic engineering and trackable genetic engineering methods.
    Type: Application
    Filed: May 1, 2023
    Publication date: October 26, 2023
    Inventors: Ryan T. GILL, Tanya WARNECKE, Dominika Joanna JEDRZEJCZYK
  • Patent number: 11795479
    Abstract: Described herein are method for generating a vector for editing a cell. The method comprises ligating into a vector that encodes a portion of a gRNA a cassette comprising at least one editing cassette, a promoter, and a gene encoding another portion of the gRNA. Upon ligation, the portion of the gRNA from the editing cassette and the other portion of the gRNA are ligated and form a functional gRNA.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 24, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Andrew Garst, Ryan T Gill
  • Publication number: 20230235363
    Abstract: The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
    Type: Application
    Filed: October 11, 2022
    Publication date: July 27, 2023
    Inventors: Ryan T. GILL, Tanya WARNECKE, Andrea BARGHETTI, Line Dahl POULSEN
  • Publication number: 20230227810
    Abstract: Provided herein are methods and composition for trackable genetic variant libraries. Further provided herein are methods and compositions for recursive engineering. Further provided herein are methods and compositions for multiplex engineering. Further provided herein are methods and compositions for enriching for editing and trackable engineered sequences and cells using nucleic acid-guided nucleases.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Ryan T. Gill, Andrew Garst, Tanya Elizabeth Warnecke Lipscomb, Marcelo Colika Bassalo, Ramsey Ibrahim Zeitoun
  • Patent number: 11702677
    Abstract: Described herein are methods and vectors for rational, multiplexed manipulation of chromosomes within open reading frames (e.g., in protein libraries) or any segment of a chromosome in a cell or population of cells, in which various CRISPR systems are used.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: July 18, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Andrew Garst, Ryan T. Gill
  • Patent number: 11697826
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: July 11, 2023
    Assignee: Inscripta, Inc.
    Inventors: Ryan T. Gill, Andrew Garst, Tanya Elizabeth Warnecke Lipscomb
  • Patent number: 11639511
    Abstract: Described herein are molecules for editing a cell. The molecules described herein generally comprise the following covalently-linked components and a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell and a region homologous to the target region comprising a change in sequence relative to the target region.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: May 2, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Andrew Garst, Ryan T Gill
  • Publication number: 20230083383
    Abstract: The present invention relates to engineered Clustered Regularly Interspaced Short Palindromic Repeals (CRISPR) systems and corresponding guide RNAs that target specific nucleotide sequences at certain gene loci in the human genome. Also provided are methods of targeting, editing, and/or modifying of the human genes using the engineered CRISPR systems, and compositions and cells comprising the engineered CRISPR systems.
    Type: Application
    Filed: February 5, 2021
    Publication date: March 16, 2023
    Applicant: DANMARKS TEKNISKE UNIVERSITET
    Inventors: Ryan T. GILL, Tanya WARNECKE, Roland Franz BAUMGARTNER
  • Patent number: 11584928
    Abstract: Provided herein are methods and composition for trackable genetic variant libraries. Further provided herein are methods and compositions for recursive engineering. Further provided herein are methods and compositions for multiplex engineering. Further provided herein are methods and compositions for enriching for editing and trackable engineered sequences and cells using nucleic acid-guided nucleases.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: February 21, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, INSCRIPTA, INC.
    Inventors: Ryan T. Gill, Andrew Garst, Tanya Elizabeth Warnecke Lipscomb, Marcelo Colika Bassalo, Ramsey Ibrahim Zeitoun
  • Publication number: 20220389417
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Application
    Filed: May 31, 2022
    Publication date: December 8, 2022
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Publication number: 20220364121
    Abstract: Described herein are molecules for editing a cell. The molecules described herein generally comprise the following covalently-linked components and a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell and a region homologous to the target region comprising a change in sequence relative to the target region.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 17, 2022
    Inventors: Andrew Garst, Ryan T Gill
  • Patent number: 11408012
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: January 29, 2022
    Date of Patent: August 9, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Publication number: 20220195464
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Patent number: 11345933
    Abstract: Described herein are synthetic oligonucleotides for editing a cell. The oligonucleotides described herein comprise the following covalently-linked components: (i) a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell; (ii) a region homologous to the target region comprising a change in sequence relative to the target region; and (iii) a site conferring immunity to nuclease-mediated editing.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 31, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Andrew Garst, Ryan T Gill
  • Publication number: 20220162646
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Application
    Filed: January 29, 2022
    Publication date: May 26, 2022
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Publication number: 20220136014
    Abstract: The present invention relates to an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system comprising engineered dual guide nucleic acids (e.g., RNAs) capable of activating a CRISPR-Associated (Cas) nuclease, such as a type V-A Cas nuclease. Also provided are methods of targeting, editing, and/or modifying a nucleic acid using the engineered CRISPR system, and compositions and cells comprising the engineered CRISPR system.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Inventors: Ryan T. GILL, Tanya WARNECKE, Andrea BARGHETTI, Line Dahl POULSEN
  • Publication number: 20220119844
    Abstract: Described herein are synthetic oligonucleotides for editing a cell. The oligonucleotides described herein comprise the following covalently-linked components: (i) a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell; (ii) a region homologous to the target region comprising a change in sequence relative to the target region; and (iii) a site conferring immunity to nuclease-mediated editing.
    Type: Application
    Filed: December 7, 2021
    Publication date: April 21, 2022
    Inventors: Andrew Garst, Ryan T Gill